Increased incidence of non-Hodgkin lymphoma, leukemia and myeloma in patients with diabetes mellitus type 2: a meta-analysis of observational studies
A partir d'une revue systématique de la littérature (13 études cas-témoins et 13 études de cohorte), cette méta-analyse évalue l'association entre un diabète de type 2 et le risque de lymphome non hodgkinien, de leucémie et de myélome
Hematologic malignancies are a heterogeneous group of conditions with an unclear etiology. We hypothesized that diabetes mellitus type 2 (DM2) is associated with increased risk of developing leukemia, lymphoma and myeloma. A literature search identified 26 studies (13 case-control and 13 cohort studies) evaluating such association. Outcome was calculated as odds ratio (OR) using a random effects model. Heterogeneity and publication bias were evaluated using the I2 index and the trim-and-fill analysis, respectively. Quality was assessed using the Newcastle-Ottawa scale. The OR for non-Hodgkin lymphoma (NHL) was increased at 1.22 (95% CI 1.07-1.39; p<0.01) but the OR for Hodgkin lymphoma was not. There was an increased OR for peripheral T-cell lymphoma (OR 2.42, 95% CI 1.24-4.72; p=0.009) but not for other NHL subtypes. The OR for leukemia was 1.22 (95% CI 1.03-1.44; p=0.02), and the OR for myeloma was 1.22 (95% CI 0.98-1.53; p=0.08). Although DM2 seems to increase the risk of developing leukemia, lymphoma and myeloma, future studies should focus on evaluating other potential confounders, such as obesity, dietary habits, physical activity and/or antidiabetic therapy.